| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 90 | 2025 | 3029 | 15.510 |
Why?
|
| Mastectomy | 50 | 2025 | 254 | 14.530 |
Why?
|
| Carcinoma, Ductal, Breast | 22 | 2022 | 160 | 7.260 |
Why?
|
| Carcinoma, Lobular | 18 | 2019 | 81 | 5.930 |
Why?
|
| Mastectomy, Segmental | 18 | 2023 | 101 | 4.030 |
Why?
|
| Surgeons | 11 | 2023 | 253 | 3.760 |
Why?
|
| Time-to-Treatment | 6 | 2025 | 126 | 3.480 |
Why?
|
| Mammaplasty | 10 | 2023 | 116 | 3.030 |
Why?
|
| Cancer Care Facilities | 5 | 2024 | 31 | 3.000 |
Why?
|
| Neoadjuvant Therapy | 10 | 2025 | 396 | 2.950 |
Why?
|
| Quality Indicators, Health Care | 6 | 2024 | 150 | 2.860 |
Why?
|
| Prophylactic Mastectomy | 8 | 2020 | 13 | 2.840 |
Why?
|
| Neoplasm Staging | 26 | 2025 | 2022 | 2.650 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 7 | 2022 | 117 | 2.310 |
Why?
|
| Female | 93 | 2025 | 47186 | 2.000 |
Why?
|
| Lymph Node Excision | 10 | 2021 | 222 | 1.970 |
Why?
|
| Receptors, Estrogen | 10 | 2022 | 395 | 1.930 |
Why?
|
| Middle Aged | 67 | 2025 | 26555 | 1.930 |
Why?
|
| Surgical Oncology | 4 | 2020 | 28 | 1.910 |
Why?
|
| Prognosis | 26 | 2024 | 3825 | 1.900 |
Why?
|
| Sentinel Lymph Node Biopsy | 12 | 2021 | 80 | 1.880 |
Why?
|
| Radiation Oncology | 3 | 2021 | 122 | 1.870 |
Why?
|
| Practice Guidelines as Topic | 8 | 2025 | 1063 | 1.800 |
Why?
|
| Accreditation | 3 | 2019 | 61 | 1.760 |
Why?
|
| Databases, Factual | 18 | 2018 | 882 | 1.760 |
Why?
|
| Aged | 53 | 2025 | 19574 | 1.680 |
Why?
|
| Aged, 80 and over | 34 | 2023 | 6847 | 1.560 |
Why?
|
| Guideline Adherence | 4 | 2018 | 234 | 1.550 |
Why?
|
| Humans | 103 | 2025 | 91074 | 1.540 |
Why?
|
| Follow-Up Studies | 21 | 2020 | 3716 | 1.530 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2020 | 1374 | 1.520 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2019 | 478 | 1.440 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2021 | 291 | 1.440 |
Why?
|
| Unilateral Breast Neoplasms | 4 | 2020 | 5 | 1.380 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2024 | 210 | 1.360 |
Why?
|
| Mastectomy, Subcutaneous | 2 | 2022 | 8 | 1.340 |
Why?
|
| Adult | 48 | 2025 | 27147 | 1.340 |
Why?
|
| Nipples | 6 | 2022 | 37 | 1.310 |
Why?
|
| United States | 29 | 2024 | 7188 | 1.210 |
Why?
|
| Thoracic Wall | 2 | 2018 | 24 | 1.200 |
Why?
|
| Receptor, ErbB-2 | 5 | 2019 | 255 | 1.180 |
Why?
|
| Lymph Nodes | 4 | 2018 | 554 | 1.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 2550 | 1.140 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2020 | 608 | 1.100 |
Why?
|
| Breast Diseases | 2 | 2022 | 101 | 1.090 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 171 | 1.060 |
Why?
|
| Neoplasm Invasiveness | 9 | 2020 | 570 | 1.060 |
Why?
|
| Ergonomics | 3 | 2022 | 23 | 1.050 |
Why?
|
| Breast Neoplasms, Male | 2 | 2023 | 31 | 1.020 |
Why?
|
| Combined Modality Therapy | 8 | 2021 | 1713 | 1.020 |
Why?
|
| Decision Making | 4 | 2019 | 675 | 1.000 |
Why?
|
| Breast | 6 | 2021 | 289 | 0.980 |
Why?
|
| Neoplasms, Second Primary | 3 | 2017 | 241 | 0.960 |
Why?
|
| Axilla | 11 | 2021 | 104 | 0.960 |
Why?
|
| Biomarkers, Tumor | 5 | 2019 | 1559 | 0.950 |
Why?
|
| Receptors, Progesterone | 6 | 2019 | 177 | 0.950 |
Why?
|
| Survival Rate | 12 | 2018 | 1898 | 0.920 |
Why?
|
| Retrospective Studies | 24 | 2024 | 9400 | 0.910 |
Why?
|
| Surveys and Questionnaires | 8 | 2023 | 2682 | 0.890 |
Why?
|
| Attitude of Health Personnel | 4 | 2023 | 652 | 0.860 |
Why?
|
| Qualitative Research | 2 | 2024 | 318 | 0.850 |
Why?
|
| Young Adult | 15 | 2024 | 6502 | 0.840 |
Why?
|
| Carcinoma | 2 | 2017 | 438 | 0.830 |
Why?
|
| Brachytherapy | 2 | 2014 | 121 | 0.820 |
Why?
|
| Patient Satisfaction | 5 | 2024 | 464 | 0.790 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 432 | 0.790 |
Why?
|
| Organ Sparing Treatments | 2 | 2019 | 47 | 0.780 |
Why?
|
| Medical Overuse | 2 | 2019 | 36 | 0.770 |
Why?
|
| Neoplasm Grading | 10 | 2018 | 376 | 0.740 |
Why?
|
| Quality of Health Care | 3 | 2018 | 388 | 0.710 |
Why?
|
| Oncologists | 1 | 2021 | 38 | 0.710 |
Why?
|
| Lymphatic Metastasis | 7 | 2018 | 500 | 0.640 |
Why?
|
| Age Factors | 9 | 2018 | 1876 | 0.640 |
Why?
|
| Burnout, Professional | 1 | 2021 | 103 | 0.640 |
Why?
|
| Pandemics | 7 | 2025 | 792 | 0.640 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2017 | 145 | 0.630 |
Why?
|
| Stereotaxic Techniques | 1 | 2019 | 80 | 0.620 |
Why?
|
| Prophylactic Surgical Procedures | 2 | 2015 | 7 | 0.620 |
Why?
|
| Patient Selection | 6 | 2019 | 685 | 0.610 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 79 | 0.600 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 322 | 0.600 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 308 | 0.600 |
Why?
|
| Reoperation | 5 | 2015 | 611 | 0.590 |
Why?
|
| Patient Care | 1 | 2019 | 101 | 0.580 |
Why?
|
| Genes, BRCA2 | 3 | 2016 | 161 | 0.580 |
Why?
|
| Radiography, Interventional | 1 | 2019 | 160 | 0.580 |
Why?
|
| Genes, BRCA1 | 3 | 2016 | 192 | 0.570 |
Why?
|
| Patient Transfer | 1 | 2018 | 102 | 0.570 |
Why?
|
| Consensus | 2 | 2016 | 374 | 0.570 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 19 | 0.570 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 38 | 0.550 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2017 | 267 | 0.550 |
Why?
|
| Radiotherapy, Conformal | 1 | 2017 | 82 | 0.550 |
Why?
|
| Logistic Models | 7 | 2017 | 1216 | 0.530 |
Why?
|
| Patient Preference | 4 | 2019 | 119 | 0.530 |
Why?
|
| Adolescent | 9 | 2024 | 9411 | 0.520 |
Why?
|
| Postoperative Complications | 7 | 2016 | 2348 | 0.510 |
Why?
|
| Societies, Medical | 2 | 2019 | 594 | 0.500 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 538 | 0.490 |
Why?
|
| Prospective Studies | 8 | 2022 | 4367 | 0.470 |
Why?
|
| Estrogen Receptor alpha | 2 | 2013 | 148 | 0.470 |
Why?
|
| Quality of Life | 4 | 2019 | 1699 | 0.450 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1753 | 0.430 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 368 | 0.430 |
Why?
|
| Elective Surgical Procedures | 1 | 2014 | 132 | 0.410 |
Why?
|
| Receptors, Notch | 2 | 2010 | 128 | 0.400 |
Why?
|
| Length of Stay | 3 | 2015 | 758 | 0.400 |
Why?
|
| Melanoma | 2 | 2009 | 475 | 0.390 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 176 | 0.390 |
Why?
|
| Skin Neoplasms | 2 | 2009 | 603 | 0.370 |
Why?
|
| Workload | 2 | 2022 | 130 | 0.360 |
Why?
|
| Operating Rooms | 2 | 2022 | 125 | 0.350 |
Why?
|
| Receptor, Notch1 | 2 | 2010 | 94 | 0.350 |
Why?
|
| Patient Readmission | 1 | 2014 | 367 | 0.340 |
Why?
|
| Registries | 1 | 2014 | 826 | 0.340 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2008 | 4 | 0.320 |
Why?
|
| Patients | 2 | 2023 | 104 | 0.320 |
Why?
|
| Socioeconomic Factors | 3 | 2016 | 596 | 0.300 |
Why?
|
| Quality Control | 2 | 2019 | 117 | 0.290 |
Why?
|
| Breast Implantation | 3 | 2016 | 14 | 0.280 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2010 | 667 | 0.280 |
Why?
|
| Calcinosis | 1 | 2008 | 230 | 0.280 |
Why?
|
| Incidence | 3 | 2023 | 1599 | 0.270 |
Why?
|
| Pilot Projects | 3 | 2019 | 887 | 0.260 |
Why?
|
| SEER Program | 3 | 2017 | 202 | 0.260 |
Why?
|
| Risk Factors | 6 | 2019 | 5608 | 0.260 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 982 | 0.260 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 863 | 0.250 |
Why?
|
| Health Care Surveys | 2 | 2018 | 280 | 0.240 |
Why?
|
| Risk Assessment | 4 | 2020 | 2345 | 0.240 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 852 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3500 | 0.240 |
Why?
|
| Referral and Consultation | 2 | 2019 | 352 | 0.230 |
Why?
|
| Appointments and Schedules | 1 | 2024 | 55 | 0.220 |
Why?
|
| Male | 9 | 2024 | 43249 | 0.220 |
Why?
|
| Biopsy | 3 | 2014 | 1196 | 0.220 |
Why?
|
| Self Concept | 1 | 2023 | 135 | 0.210 |
Why?
|
| Time Factors | 5 | 2016 | 5378 | 0.210 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 468 | 0.200 |
Why?
|
| Cohort Studies | 4 | 2018 | 2904 | 0.180 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 1465 | 0.170 |
Why?
|
| Betacoronavirus | 2 | 2020 | 264 | 0.170 |
Why?
|
| Mammography | 2 | 2017 | 470 | 0.170 |
Why?
|
| Personnel Selection | 1 | 2020 | 62 | 0.170 |
Why?
|
| Health Resources | 1 | 2020 | 81 | 0.160 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2018 | 259 | 0.160 |
Why?
|
| Body Image | 1 | 2019 | 80 | 0.160 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 1093 | 0.160 |
Why?
|
| Specialties, Surgical | 1 | 2020 | 70 | 0.160 |
Why?
|
| Fear | 1 | 2019 | 80 | 0.160 |
Why?
|
| Triage | 1 | 2020 | 120 | 0.160 |
Why?
|
| User-Computer Interface | 1 | 2020 | 187 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2020 | 348 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2018 | 8436 | 0.160 |
Why?
|
| Breast Implants | 2 | 2016 | 27 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 301 | 0.160 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 130 | 0.150 |
Why?
|
| Anxiety | 1 | 2021 | 316 | 0.150 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2018 | 6 | 0.150 |
Why?
|
| Video Recording | 1 | 2019 | 204 | 0.150 |
Why?
|
| Databases as Topic | 1 | 2018 | 94 | 0.150 |
Why?
|
| Emotions | 1 | 2021 | 359 | 0.140 |
Why?
|
| Patient Participation | 1 | 2019 | 227 | 0.140 |
Why?
|
| Patient Compliance | 1 | 2018 | 231 | 0.140 |
Why?
|
| Choice Behavior | 1 | 2018 | 162 | 0.140 |
Why?
|
| Telemedicine | 1 | 2020 | 200 | 0.140 |
Why?
|
| Heterozygote | 2 | 2016 | 374 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 681 | 0.140 |
Why?
|
| Sleep | 1 | 2021 | 458 | 0.130 |
Why?
|
| Ultrasonography, Mammary | 1 | 2017 | 83 | 0.130 |
Why?
|
| Disease Management | 1 | 2018 | 336 | 0.130 |
Why?
|
| Surgical Wound Infection | 2 | 2015 | 205 | 0.130 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 188 | 0.130 |
Why?
|
| Esthetics | 1 | 2016 | 45 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2016 | 68 | 0.130 |
Why?
|
| Molecular Typing | 1 | 2015 | 17 | 0.130 |
Why?
|
| Illinois | 1 | 2017 | 499 | 0.130 |
Why?
|
| Comprehension | 1 | 2016 | 81 | 0.130 |
Why?
|
| Europe | 1 | 2016 | 329 | 0.120 |
Why?
|
| Pharyngectomy | 1 | 2015 | 8 | 0.120 |
Why?
|
| Neoplasms | 2 | 2022 | 3053 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2016 | 209 | 0.120 |
Why?
|
| Remission Induction | 1 | 2017 | 756 | 0.120 |
Why?
|
| Immunohistochemistry | 2 | 2010 | 1806 | 0.120 |
Why?
|
| Physicians | 2 | 2019 | 691 | 0.120 |
Why?
|
| Counseling | 1 | 2016 | 169 | 0.120 |
Why?
|
| Carcinoma in Situ | 1 | 2015 | 53 | 0.120 |
Why?
|
| Selection Bias | 1 | 2014 | 36 | 0.120 |
Why?
|
| Linear Models | 1 | 2015 | 426 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 1066 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1877 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 318 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 977 | 0.110 |
Why?
|
| Adipokines | 1 | 2013 | 17 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 481 | 0.110 |
Why?
|
| Receptor, Notch4 | 2 | 2010 | 5 | 0.110 |
Why?
|
| Insurance, Health | 1 | 2014 | 164 | 0.110 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2015 | 132 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 854 | 0.110 |
Why?
|
| Fatty Acids | 1 | 2013 | 141 | 0.100 |
Why?
|
| Surgical Flaps | 1 | 2015 | 254 | 0.100 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 327 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 162 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2013 | 263 | 0.090 |
Why?
|
| Models, Biological | 1 | 2018 | 1771 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2785 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 439 | 0.090 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2010 | 13 | 0.090 |
Why?
|
| Jagged-1 Protein | 1 | 2010 | 13 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 1087 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 1295 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 1 | 2010 | 121 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 2380 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 183 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2008 | 222 | 0.080 |
Why?
|
| Receptor Cross-Talk | 1 | 2008 | 33 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2009 | 214 | 0.080 |
Why?
|
| Hemostatics | 1 | 2008 | 58 | 0.080 |
Why?
|
| Quality Improvement | 2 | 2022 | 460 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2008 | 70 | 0.070 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 427 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 1095 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 233 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 360 | 0.070 |
Why?
|
| Hyperplasia | 1 | 2008 | 153 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2009 | 172 | 0.070 |
Why?
|
| Cancer Vaccines | 1 | 2009 | 164 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 181 | 0.070 |
Why?
|
| Obesity | 1 | 2013 | 989 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 897 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2012 | 2033 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 1169 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2020 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1237 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1750 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2013 | 303 | 0.050 |
Why?
|
| Mutation | 1 | 2014 | 4203 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2020 | 43 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2013 | 1049 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2023 | 544 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 313 | 0.040 |
Why?
|
| Fees and Charges | 1 | 2018 | 14 | 0.040 |
Why?
|
| Hospital Charges | 1 | 2018 | 29 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2018 | 21 | 0.040 |
Why?
|
| Mass Screening | 1 | 2022 | 646 | 0.040 |
Why?
|
| Propensity Score | 1 | 2018 | 156 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 338 | 0.030 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 150 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 235 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2017 | 316 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1452 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 785 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1695 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2018 | 476 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 300 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 120 | 0.030 |
Why?
|
| Communication | 1 | 2018 | 462 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2015 | 170 | 0.030 |
Why?
|
| Lipase | 1 | 2013 | 21 | 0.030 |
Why?
|
| Serpins | 1 | 2013 | 32 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 351 | 0.030 |
Why?
|
| Nerve Growth Factors | 1 | 2013 | 63 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 657 | 0.030 |
Why?
|
| Leptin | 1 | 2013 | 103 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 627 | 0.030 |
Why?
|
| Eye Proteins | 1 | 2013 | 129 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2012 | 95 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 67 | 0.030 |
Why?
|
| Contraindications | 1 | 2012 | 70 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 355 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 963 | 0.020 |
Why?
|
| Sepsis | 1 | 2015 | 330 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 784 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2008 | 36 | 0.020 |
Why?
|
| Estradiol | 1 | 2008 | 250 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 492 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 557 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 821 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1102 | 0.020 |
Why?
|
| Mice | 1 | 2008 | 11993 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 27783 | 0.000 |
Why?
|